ZYBERNO
Stock Report
Updated Aug 31, 2026

DAMORA THERAPEUTICS, INC. (DMRA)

Healthcare • NASDAQ

$29.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
DAMORA THERAPEUTICS, INC. (DMRA) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-82.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-6,504.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

DAMORA THERAPEUTICS, INC. (DMRA) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:29.00
Market Cap:$1.77B

Valuation Multiples (3)

P/B Ratio:3.43x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.23B

Price Action & Momentum (1)

% of 52-Week High:83.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-77.9%
Reinvestment Rate:-8.6%
Fundamental Growth Rate (g):556.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:$25.83
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-130.9%
Latest Earnings Filed:2026-08-10
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:19.73x
Quick Ratio:19.73x
Cash Ratio:19.62x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-25.80x
Times Interest Earned:-25.80

Capital Structure (4)

Working Capital:516,038,000.00
Cash And Cash Equivalents:540,515,000.00
Long Term Debt:$27.00K
Net Debt:-$540.47M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$270.66M

Bottom Line Performance (3)

-$262.83M
Income Before Tax:-$262.49M
Ebitda Ttm:-270,635,000.00

Operating Expenses (5)

Operating Expenses:270,657,000.00
R And D Expense:74,051,000.00
Sga Expense:22,296,000.00
Income Tax Expense:$341.00K
Interest Expense:8,172,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$543.64M
Current Assets:$543.59M
Ppe Net:36,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:27,577,000.00
Current Liabilities:27,550,000.00
Long Term Debt:$27.00K
Short Term Debt:$15.00K

Equity & Capital (3)

Equity:$516.06M
Retained Earnings:-$546.32M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,482,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:10,687,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$24.89M$0.00

Investment Activities (1)

Investing Cash Flow:-$29.02M

Financing Activities (3)

Financing Cash Flow:$295.92M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:22,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):7.49
$7.49
Earnings Per Share Ttm:-$4.30

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.11

Book Value & Capital (2)

Book Value Per Share:$8.44
Cash Per Share:8.84

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-8.6%
Fundamental Growth Rate (g):556.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):10.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:DMRA
Company Name:DAMORA THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:61.12M
Shares Outstanding Basic:61.12M
Shares Outstanding Diluted:61.12M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 20:20:37 UTC
Data Timestamp:2026-08-31T20:20:37.758096
Scroll to Top